Sun Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries Ltd (SUNPHARMA) last reported results for the quarter ended Jun 2026, with sales of ₹15,300 crore and net profit of ₹2,901 crore. Sun Pharmaceutical Industries Ltd’s board meets on 12 Oct 2026. The stock last traded at ₹1,778, a market capitalisation of ₹4,26,602 crore, on a P/E of 33.8. Over the past 52 weeks the stock has ranged between ₹1,584 and ₹2,048. Figures are as of 6 Oct 2026 and are not real time.
Sun Pharmaceutical Industries Ltd share price and key metrics
- Current price
- ₹1,778
- Market cap
- ₹4,26,602 cr
- Stock P/E
- 33.8
- Book value
- ₹348
- ROE
- 16.0%
- ROCE
- 20.5%
- Dividend yield
- 0.90%
- 52w high / low
- 2048/1584
Metrics as of 6 Oct 2026. Not real time.
Track Sun Pharmaceutical Industries Ltd
Cruxal reads every Sun Pharmaceutical Industries Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Sun Pharmaceutical Industries Ltd growth and returns
- 10 Years
- 7%
- 5 Years
- 12%
- 3 Years
- 10%
- TTM
- 11%
- 10 Years
- 10%
- 5 Years
- 17%
- 3 Years
- 13%
- TTM
- 10%
- 10 Years
- 9%
- 5 Years
- 17%
- 3 Years
- 16%
- 1 Year
- 8%
- 10 Years
- 14%
- 5 Years
- 16%
- 3 Years
- 16%
- Last Year
- 16%
Sun Pharmaceutical Industries Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹15,300 cr, up 10.5% from ₹13,851 cr a year earlier. Net profit was ₹2,901 cr, up 26.5% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 13,291 | 13,675 | 12,959 | 13,851 | 14,478 | 15,521 | 14,612 | 15,300 |
| Expenses | 9,352 | 9,666 | 9,243 | 9,550 | 9,951 | 10,572 | 10,658 | 10,882 |
| Operating profit | 3,939 | 4,009 | 3,716 | 4,302 | 4,527 | 4,948 | 3,954 | 4,418 |
| OPM % | 30% | 29% | 29% | 31% | 31% | 32% | 27% | 29% |
| Other income | 354 | 149 | 251 | -354 | 470 | 89 | 458 | 520 |
| Interest | 69 | 52 | 49 | 75 | 100 | 78 | 86 | 100 |
| Depreciation | 626 | 631 | 664 | 701 | 730 | 732 | 775 | 739 |
| Profit before tax | 3,598 | 3,476 | 3,254 | 3,173 | 4,168 | 4,227 | 3,551 | 4,099 |
| Tax % | 16% | 16% | 34% | 27% | 25% | 20% | 23% | 29% |
| Net profit | 3,037 | 2,913 | 2,154 | 2,293 | 3,125 | 3,381 | 2,710 | 2,901 |
| EPS (₹) | 12.67 | 12.10 | 8.96 | 9.50 | 13.00 | 14.04 | 11.31 | 12.06 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Sun Pharmaceutical Industries Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 31,578 | 26,489 | 29,066 | 32,838 | 33,498 | 38,654 | 43,886 | 48,497 | 52,578 | 58,462 | 59,911 |
| Operating profit | 10,102 | 5,631 | 6,377 | 6,983 | 8,470 | 10,258 | 11,650 | 13,018 | 15,114 | 16,501 | 17,847 |
| OPM % | 32% | 21% | 22% | 21% | 25% | 27% | 27% | 27% | 29% | 28% | 30% |
| Net profit | 7,846 | 2,542 | 3,208 | 4,172 | 2,272 | 3,389 | 8,513 | 9,610 | 10,965 | 11,509 | 12,117 |
| EPS (₹) | 29.03 | 8.73 | 11.11 | 15.69 | 12.10 | 13.64 | 35.32 | 39.91 | 45.55 | 47.84 | 50.41 |
TTM is the trailing twelve months to the most recent quarter.
Sun Pharmaceutical Industries Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 240 | 240 | 240 | 240 | 240 | 240 | 240 | 240 | 240 | 240 |
| Reserves | 36,400 | 38,074 | 41,169 | 45,025 | 46,223 | 47,771 | 55,755 | 63,427 | 71,978 | 83,330 |
| Borrowings | 9,832 | 10,385 | 10,514 | 8,315 | 3,869 | 1,290 | 6,886 | 3,274 | 2,362 | 4,627 |
| Other liabilities | 14,624 | 15,598 | 12,666 | 14,615 | 17,291 | 20,474 | 17,831 | 18,387 | 17,328 | 20,210 |
| Total liabilities | 61,095 | 64,297 | 64,590 | 68,194 | 67,622 | 69,776 | 80,712 | 85,328 | 91,908 | 108,407 |
| Fixed assets | 17,675 | 18,853 | 21,837 | 22,847 | 21,553 | 22,665 | 24,065 | 23,248 | 22,586 | 32,822 |
| CWIP | 2,801 | 2,465 | 1,411 | 1,220 | 1,567 | 1,287 | 4,973 | 5,354 | 6,644 | 3,052 |
| Investments | 1,192 | 7,143 | 7,903 | 10,143 | 9,612 | 12,849 | 14,824 | 15,026 | 18,354 | 24,723 |
| Other assets | 39,427 | 35,837 | 33,439 | 33,984 | 34,890 | 32,975 | 36,849 | 41,700 | 44,324 | 47,811 |
| Total assets | 61,095 | 64,297 | 64,590 | 68,194 | 67,622 | 69,776 | 80,712 | 85,328 | 91,908 | 108,407 |
As reported by the company. Total assets equal total liabilities by construction.
Sun Pharmaceutical Industries Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 7,082 | 3,907 | 2,196 | 6,555 | 6,170 | 8,985 | 4,959 | 12,135 | 14,072 | 12,419 |
| Cash from investing | -4,186 | -3,104 | -310 | -2,225 | 407 | -5,556 | -7,220 | -763 | -5,183 | -10,405 |
| Cash from financing | -2,285 | -1,539 | -2,731 | -5,715 | -5,980 | -5,193 | 2,376 | -6,710 | -7,906 | -2,513 |
| Net cash flow | 611 | -736 | -844 | -1,386 | 596 | -1,765 | 115 | 4,662 | 983 | -498 |
| Free cash flow | 3,492 | 2,013 | -966 | 5,105 | 5,097 | 7,550 | 2,895 | 9,964 | 12,005 | 8,906 |
| CFO / operating profit | 90% | 83% | 48% | 113% | 85% | 78% | 56% | 105% | 96% | 89% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Sun Pharmaceutical Industries Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 20% | 10% | 10% | 10% | 13% | 17% | 16% | 17% | 20% | 21% |
| Debtor days | 83 | 108 | 112 | 105 | 99 | 99 | 95 | 85 | 91 | 97 |
| Inventory days | 307 | 338 | 366 | 311 | 378 | 315 | 360 | 338 | 348 | 363 |
| Days payable | 197 | 234 | 192 | 142 | 167 | 158 | 194 | 194 | 210 | 232 |
| Cash conversion cycle | 193 | 212 | 285 | 274 | 310 | 255 | 261 | 229 | 228 | 228 |
| Working capital days | -4 | -31 | 31 | 51 | 51 | 47 | 40 | 55 | 65 | 54 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Sun Pharmaceutical Industries Ltd shareholding pattern
Promoters held 54.48% at Jun 2026, broadly unchanged since Jun 2025. FIIs 14.54% and DIIs 22.06%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 54.48% | 54.48% | 54.48% | 54.48% | 54.48% | 54.48% | 54.48% | 54.48% |
| FIIs | 18.01% | 18.04% | 17.96% | 17.26% | 16.55% | 16.12% | 15.94% | 14.54% |
| DIIs | 18.48% | 18.43% | 18.58% | 19.38% | 20.12% | 20.72% | 21.00% | 22.06% |
| Government | 0.11% | 0.11% | 0.11% | 0.11% | 0.11% | 0.11% | 0.11% | 0.11% |
| Public | 8.89% | 8.92% | 8.86% | 8.76% | 8.72% | 8.57% | 8.48% | 8.81% |
| No. of shareholders | 6,57,317 | 6,89,623 | 7,04,983 | 7,23,770 | 7,43,877 | 7,10,900 | 6,90,957 | 7,10,246 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
When does Sun Pharmaceutical Industries Ltd’s board next meet?
Sun Pharmaceutical Industries Ltd’s board meets on 12 Oct 2026.
- Board meetingConsideration and approval of issuance of non-convertible debentures (NCDs) for INR 15,000 crore
- Shareholder meeting|fundraising|stock option plan|merger acquisitionApproval of ESOP 2026, secondary acquisition of shares, extension to subsidiaries, and funding limits for proposed acquisition of Organon
- Public announcementIntimation of upcoming shareholder meeting and related disclosures
See the full results calendar for every Indian company reporting in the next 30 days.
Cruxal coverage of Sun Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries Ltd corporate filings
- Sun Pharmaceutical to Raise INR 15,000 Crore via Private Placement of Unsecured NCDsBoard Meetinghigh impact
Cruxal's analysis: Sun Pharmaceutical Industries Limited has announced a scheduled Board meeting on 12…
Read the full analysis - Sun Pharma releases press statement; no financial impact disclosedCompany Updatelow impact
Cruxal's analysis: Sun Pharmaceutical Industries Ltd issued a press release on October 6, 2026. The…
Read the full analysis - Sun Pharma publishes newspaper notice for Postal Ballot/E-voting scheduled for October 2026Company Updatelow impact
Cruxal's analysis: The company has announced a newspaper publication regarding the postal ballot and…
Read the full analysis - Sun Pharma seeks shareholder approval for multiple strategic and financial initiatives including ESOP 2026, secondary share acquisition, and significant funding limits for upcoming M&A activities.AGM/EGMhigh impact
Cruxal's analysis: Sun Pharma is proposing a comprehensive package of approvals to implement its ESOP 2026…
Read the full analysis - Sun Pharmaceutical Industries releases a press statement; no financial or operational details disclosedCompany Updatelow impact
Cruxal's analysis: The company has issued a press release under Regulation 30, with no additional financial…
Read the full analysis - Sun Pharma publishes newspaper notice on opening of Special Window for physical share transfersCompany Updatelow impact
Cruxal's analysis: Sun Pharmaceutical Industries Ltd announced via newspaper publication the opening of a…
Read the full analysis - Sun Pharma releases ESG overview for FY 2025-26, no financial impact disclosedCompany Updatelow impact
Cruxal's analysis: Sun Pharmaceutical Industries Ltd announced its ESG overview for FY 2025-26 on September…
Read the full analysis - Sun Pharmaceutical Industries Limited announces successful completion of postal ballot processCompany Updatelow impact
Cruxal's analysis: Sun Pharmaceutical Industries Limited has formally announced the completion of its postal…
Read the full analysis - Sun Pharma enters into licensing agreement for lerodalcibepCompany Updatemedium impact
Cruxal's analysis: Sun Pharmaceutical Industries has announced a licensing agreement for lerodalcibep, a…
Read the full analysis - Sun Pharmaceutical Industries receives shareholder approval for reclassification of shareholder categoryCompany Updatelow impact
Cruxal's analysis: Sun Pharmaceutical Industries has received formal approval from its shareholders for the…
Read the full analysis - Trading Window closureInsider Trading / SASTlow impact
- Sun Pharma Investor Presentation Highlights Strong FY26 Performance and Strategic Growth in Innovative MedicinesCompany Updatehigh impact
Cruxal's analysis: Sun Pharmaceutical Industries Limited has released its September 2026 investor…
Read the full analysis - Sun Pharmaceutical Industries Ltd: Intimation under Regulation 30 of SEBI LODRCompany Updatelow impact
Cruxal's analysis: Sun Pharmaceutical Industries Ltd has filed a routine intimation under Regulation 30 of…
Read the full analysis - Sun Pharmaceutical Industries incorporates wholly owned subsidiary in GIFT City, GujaratCompany Updatelow impact
Cruxal's analysis: Sun Pharmaceutical Industries has incorporated a new wholly owned subsidiary in the…
Read the full analysis - Sun Pharma Assigned Investment-Grade Credit Ratings by Moody's and S&P Following Proposed $11.75 Billion Acquisition of OrganonCompany Updatehigh impact
Cruxal's analysis: Sun Pharmaceutical Industries Limited has been assigned international issuer credit…
Read the full analysis - Sun Pharmaceutical Industries Ltd schedules analyst/institutional investor meetingCompany Updatelow impact
Cruxal's analysis: Sun Pharmaceutical Industries Ltd has issued an intimation regarding a scheduled meeting…
Read the full analysis - Sun Pharma participates in White House ceremony regarding U.S. medicine pricing and access commitmentsCompany Updatelow impact
Cruxal's analysis: Sun Pharmaceutical Industries Ltd announced its participation in a White House signing…
Read the full analysis - Sun Pharmaceutical Industries Ltd publishes newspaper advertisements regarding Postal Ballot and E-votingCompany Updatelow impact
Cruxal's analysis: Sun Pharmaceutical Industries Ltd has completed the mandatory newspaper publication…
Read the full analysis - Sun Pharmaceutical Industries Limited initiates shareholder approval for reclassification of promoter group members to public categoryAGM/EGMlow impact
Cruxal's analysis: Sun Pharmaceutical Industries Limited has issued a notice for a postal ballot to seek…
Read the full analysis - Sun Pharmaceutical Industries Ltd schedules analyst/institutional investor meetingCompany Updatelow impact
Cruxal's analysis: Sun Pharmaceutical Industries Ltd has issued an intimation regarding a scheduled meeting…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.